Expert perspectives on
the BIM-IOL System and
the burden of glaucoma

Hear a leading ophthalmic surgeon’s perspective on Phase 1/2 interim data

Dr. Cathleen McCabe discusses key results from 12-month interim data.

FPO

Phase 1/2 Interim Data at 12 Months:
A Review

Cathleen McCabe, MD

Watch experts discuss the changing landscape of glaucoma treatment for all cataract surgeons

Hear how emerging longer-term data may inform the future of sustained drug delivery.*

FPO

Rethinking Glaucoma Management in Comprehensive Ophthalmology

Darrell White, MD

FPO

Seamless Integration of Sustained Drug Delivery Into Cataract Surgery

Jai G. Parekh, MD, MBA, FAAO

FPO

What Sustained Drug Delivery Could Mean for Glaucoma Care

Preeya Gupta, MD

FPO

Consistent Drug Delivery Without the
Burden of Drops

Sam Garg, MD

Explore the future of our sustained drug delivery platform.